Teva moves anti-IL-15 antibody to Phase 2b for vitiligo treatment

Cevap yazmak için giriş yap yada kayıt ol.
Benzer konular Forum Tarih
A UBS reiterates Buy on Teva Pharma stock, keeps $42 price target Hisse Senetleri 0 11
A Corteva’s SWOT analysis: agribusiness stock shows growth potential Hisse Senetleri 0 10
A Jefferies reiterates Teva stock rating on pipeline potential Hisse Senetleri 0 40
A Corteva targets fourth quarter for planned split into two companies Hisse Senetleri 0 29
A Corteva VP Titus sells $636,199 in CTVA stock Hisse Senetleri 0 28
A Form 144 Corteva For: 20 February Hisse Senetleri 0 32
A EU approves Teva's bone health biosimilars for European markets Hisse Senetleri 0 29
A Earnings call transcript: Corteva's Q3 2025 beats forecasts, stock rises Hisse Senetleri 0 45

Benzer konular

Üst